Microdosing for depression is the practice of taking a sub-perceptual dose of a psychedelic, typically 0.1 to 0.3 grams of dried psilocybin mushroom, on a recurring schedule, with the goal of reducing depressive symptoms. Rootman et al. (Scientific Reports, 2022), in a 30-day longitudinal study of 8,703 microdosers and non-microdosing comparators, reported that microdosers showed larger improvements in depression, anxiety, and stress than non-microdosing controls (Rootman et al., Scientific Reports, 2022). That is the strongest naturalistic signal we have. The most rigorous controlled trial points the other way.
The 2021 Szigeti self-blinding randomized controlled trial (eLife) found that mood and wellbeing improvements were statistically indistinguishable between microdosing and placebo groups across 191 participants. Polito and Stevenson (PLoS One, 2019) added a third data point: in a 30-day prospective protocol with 98 microdosers, depressive symptoms decreased significantly, but there was no placebo arm to test what was actually doing the work. For broader context, see the microdosing psilocybin research overview.
The honest 2026 picture, then, has three layers. Microdosers reliably report depression reductions. Controlled trials find the substance is not clearly the cause. Full-dose psilocybin therapy, a completely different intervention, has real remission data: Goodwin et al. (NEJM, 2022) reported 29% sustained remission in treatment-resistant depression at week three with a single 25mg COMP360 session. This article walks through what each of those findings actually means, where microdosing fits as an adjunct rather than a replacement, and what the founder population using microdose-as-self-treatment is missing.
- Rootman et al. (Scientific Reports, 2022) tracked 8,703 microdosers and found larger depression, anxiety, and stress reductions versus non-microdosing controls over 30 days.
- The 2021 Szigeti self-blinding RCT (eLife) found near-zero objective effect of microdosing over placebo on mood outcomes, suggesting expectation accounts for most of the felt benefit.
- Goodwin et al. (NEJM, 2022) reported 29% sustained remission in treatment-resistant depression at week three from a single 25mg COMP360 psilocybin session, an effect size microdosing has never demonstrated.
- Cost differential is stark: a months-long microdose protocol typically runs around $200, while a single full-dose clinical psilocybin session in regulated jurisdictions runs $5,000 or more.
- Microdosing is best understood as an adjunct or maintenance option for mild depressive symptoms, not as a replacement for evidence-based treatment of moderate or severe depression.
What Does the Evidence on Microdosing for Depression Actually Show?
The Rootman 2022 study in Scientific Reports remains the largest naturalistic dataset, with 8,703 participants tracked over 30 days, showing microdosers improved on depression, anxiety, and stress measures more than non-microdosing comparators (Rootman et al., Scientific Reports, 2022). The effect sizes were small to moderate, the design was observational, and the result is the strongest user-reported signal in the literature.
Two other studies form the user-reported backbone. Polito and Stevenson (PLoS One, 2019) followed 98 microdosers prospectively across a 30-day Fadiman-style protocol and documented significant reductions in self-reported depression and stress alongside gains in focus and creativity. Anderson et al. (Harm Reduction Journal, 2019) surveyed 909 microdosers cross-sectionally and found mood improvement as the second most reported benefit after focus. The user-reported evidence is consistent across three independent samples.
The controlled evidence tells a different story. The Szigeti 2021 self-blinding RCT, the largest placebo-controlled microdosing study to date, found that subjective improvements in psychological functioning, including depression-relevant outcomes, appeared in placebo participants at rates indistinguishable from active microdosing. The implication is not that microdosers are wrong about feeling better. The implication is that the felt improvement and the substance are not tightly linked.
Rootman et al. (Scientific Reports, 2022) tracked 8,703 microdosers and non-microdosing comparators over 30 days and reported larger reductions in depression, anxiety, and stress in the microdosing group, the strongest naturalistic depression signal in the literature. Polito and Stevenson (PLoS One, 2019) found similar self-reported antidepressant effects across a 98-participant 30-day prospective protocol. Szigeti et al. (eLife, 2021) ran a self-blinding placebo-controlled trial of 191 microdosers and found that mood and wellbeing improvements appeared at statistically indistinguishable rates in active and placebo groups. The clean reading across the three studies: microdosing reliably produces felt depression relief, the substance itself is not clearly the cause, and protocol structure, expectation, and increased attention to mental state account for most of the measurable effect.
For someone in active depression weighing whether to try microdosing, this matters more than the headline numbers suggest. The protocol may help. The molecule may or may not be doing the work. And the gap between feeling better and being objectively better, by clinical criteria, is exactly where microdosing struggles to make its case against established treatments.
Why Do Rootman and Szigeti Reach Such Different Conclusions?
The two studies disagree because they answer different questions. Rootman 2022 asks whether microdosers feel less depressed than non-microdosers, with no placebo control. Szigeti 2021 asks whether psilocybin produces a mood effect above and beyond expectation, with rigorous placebo control. Both questions are legitimate. Their answers point in opposite directions because expectation effects are large in depression and microdosing alike.
The Rootman design is observational. Participants self-selected into microdosing. They knew they were microdosing. They believed the substance was helping. Their non-microdosing comparators did not have a parallel protocol, ritual, or expectation. Differences between groups could come from the molecule or from everything else that comes with adopting a microdosing practice: rest days, journaling, reduced alcohol, attention to mood, and a story about taking deliberate action on mental health.
The Szigeti et al. 2021 design tries to isolate the molecule. Participants prepared capsules at home using a randomization that kept them genuinely blind to whether they were ingesting psilocybin or placebo. Both groups underwent the same protocol structure. Both groups improved. Both groups improved by roughly the same amount. When the protocol is held constant and only the molecule varies, the molecule disappears as a discrete cause.
This is not a contradiction. It is a structural feature of how depression responds to interventions. Placebo response rates in depression trials run between 30 and 40% in many SSRI trials. The active drug needs to clear that bar, not start from zero. Microdosing has not yet cleared the placebo bar in the one controlled comparison we have. The user-reported gains are real. The pharmacological case for the substance as the active ingredient is, on the cleanest available evidence, weak.
What This Means for People Considering It
The decision is not whether microdosing produces felt benefit. It almost certainly will, particularly for mild symptoms in someone who has not previously kept a mood journal, paid close attention to sleep, or built rest structure into their week. The decision is whether the felt benefit needs the substance to occur, whether the regulatory and unknown-long-term-risk cost is worth paying for an effect that the controlled data suggests is largely expectation-mediated, and whether other evidence-based options have been tried first.
How Does Microdosing Compare to SSRIs for Depression?
SSRIs have decades of randomized controlled trial evidence supporting roughly 50 to 60% response rates in moderate to severe depression in primary care populations, with a well-characterized side-effect profile. Microdosing has the inverse evidence picture: strong naturalistic signal, near-zero controlled effect over placebo, and a poorly characterized long-term safety profile. The two interventions are not really on the same evidence shelf.
The mechanism pictures also differ. SSRIs occupy serotonin reuptake transporters, raising synaptic serotonin gradually over weeks. Effects typically emerge over four to six weeks of consistent dosing. Microdose psilocybin, by contrast, hits 5-HT2A receptors directly on dose days, with no synaptic-serotonin elevation in between. Whether that receptor profile produces antidepressant effects at sub-perceptual doses is exactly the question Szigeti tried to answer, and the answer was, on the cleanest measure available, essentially no.
For mild depression in a person who has never tried any structured intervention, microdosing may produce comparable felt improvement to an SSRI in the short term, largely through expectation and behavior-change pathways. For moderate or severe depression, the comparison breaks down. SSRIs have remission data. Microdosing does not. Choosing microdosing over a clinically indicated SSRI for moderate depression trades a known intervention with known side effects for an under-evidenced one with unknown long-term effects. For people considering this trade, see SSRIs and psychedelics.
The mechanistic gap between SSRIs and microdose psilocybin is widening as Phase 3 evidence accumulates. SSRIs work by chronic synaptic serotonin elevation, requiring 4-6 weeks for measurable mood effect and producing 50-60% response in major depression (STAR*D, n=2876). Full-dose psilocybin works via acute 5-HT2A agonism that drives BDNF-mediated synaptic plasticity for 2-4 weeks post-session, with COMP360 achieving 29% sustained remission in TRD at 3 weeks from a single dose (Goodwin 2022 NEJM). Microdosing sits between these two paradigms in dose but achieves neither chronic serotonergic saturation nor acute high-intensity 5-HT2A activation. The clinical question is whether sub-perceptual dosing accumulates enough plasticity effect to matter, or whether the protocol structure carries the outcome.
The Co-Administration Question
A surprising number of people quietly microdose while on SSRIs. The interaction picture is more nuanced than online communities tend to present it. Standard SSRIs occupy reuptake transporters, which can blunt the subjective response to psychedelics, including microdoses. Acute serotonin syndrome risk from microdose-level psilocybin combined with a single SSRI is low but not zero. Monoamine oxidase inhibitors combined with psilocybin are a different matter and are contraindicated.
Anyone considering microdosing while on an antidepressant should be working with a clinician who can monitor for serotonergic symptoms and discuss whether tapering, switching, or maintaining the antidepressant is the right move. The unstudied long-term picture is the bigger concern, not the acute interaction.
How Does Microdose Compare to Full-Dose Psilocybin Therapy?
Goodwin et al. (NEJM, 2022) reported that a single 25mg COMP360 psilocybin dose produced 29% sustained remission in treatment-resistant depression at week three, with effects measurable out to week twelve in a substantial minority of participants (Goodwin et al., NEJM, 2022). This is the kind of effect size microdosing has never demonstrated, and the comparison clarifies what each intervention actually is.
The two are different drugs in functional terms. Full-dose psilocybin therapy involves a single, high-dose, supervised session designed to produce a fully immersive psychedelic experience, typically supported by preparation and integration. The mechanism appears to involve transient hyperconnectivity in default-mode and salience networks, sometimes followed by lasting shifts in patterns of self-referential thinking. Microdosing produces no comparable acute experience and does not engage the network-disruption mechanism that full-dose work appears to use.
The table below summarizes how the three main pharmacological options compare on mechanism, evidence base, cost, and time horizon for someone considering them for depression.
| Dimension | Microdose psilocybin | Full-dose psilocybin therapy | SSRI |
|---|---|---|---|
| Primary mechanism | Sub-perceptual 5-HT2A activation, no acute experience | Acute network disruption plus sustained neuroplasticity window | Chronic serotonin reuptake inhibition |
| Best controlled evidence | Szigeti 2021: near-zero objective effect over placebo | Goodwin 2022 NEJM: 29% sustained remission in TRD at week 3 | Decades of RCTs, roughly 50-60% response rate in moderate-severe depression |
| Best naturalistic signal | Rootman 2022: depression reductions in 8,703 users | Open-label trials show sustained response in roughly 50% | Real-world remission roughly 30-40% in primary care |
| Approximate cost | Around $200 for a months-long protocol | $5,000 or more per session in regulated jurisdictions | $10 to $100 per month plus clinician follow-up |
| Time to felt effect | Variable, often days to weeks of subjective shift | Same-day acute experience, sustained benefit over weeks | Typically 4 to 6 weeks for full antidepressant effect |
| Best-fit indication | Mild symptoms, maintenance, or adjunct, not primary treatment | Treatment-resistant depression, in supervised clinical contexts | Moderate to severe depression with primary care or psychiatric access |
For deeper detail on the high-dose model, see psychedelic therapy for depression. The relevant point for this article is that microdosing and full-dose psilocybin should not be lumped together in the public conversation. They are different interventions with different evidence bases, different costs, different risk profiles, and different indications. Conflating them is one of the most common errors I see in founder self-treatment.
"Microdosing for depression makes sense as an adjunct or a maintenance frame for mild symptoms. It does not make sense as a replacement for treatment in moderate or severe depression, and most people using it that way are running an under-evidenced experiment on themselves while better options sit unused."
Who Might Microdosing for Depression Actually Help?
The population where microdosing has the strongest plausible case is mild-symptom users who have not previously engaged any structured intervention and who are not candidates for clinical-grade depression treatment. For this group, the protocol structure, the felt placebo response, and the behavioral changes that come with the practice can produce meaningful relief, regardless of whether the molecule is the active ingredient.
Across the integration work I do, the founders and executives who come to me having microdosed for depression cluster into three patterns. The first group is genuinely mild: low-grade dysphoria, mild anhedonia, professional friction. For them, the protocol usually does produce a real shift, and the question of whether the substance is the cause matters less because the cost-benefit math is favorable. The second group has moderate depression that has not been formally assessed, and the microdose is functioning as a delay on getting real care. The third group has treatment-resistant depression and is using microdosing because clinical psilocybin is unavailable to them, which is a legitimate but difficult position.
The first group is where microdosing fits cleanly. The second group is where it does the most harm, not because the substance is dangerous but because it papers over the case for actual treatment. The third group needs a different conversation entirely, one that recognizes the access constraint as the real problem and treats microdosing as the lowest-evidence option in a portfolio that should also include psychotherapy, ketamine, and full-dose work where geographically possible. See psychedelics for entrepreneurs for related context on the founder population.
The Pattern Most Founders Miss
When someone tells me they have been microdosing for depression for six months and the felt benefit is fading, the question I ask is not about the dose or the protocol. It is about what the depression is doing underneath. Microdosing tends to soften the affective signal without changing the underlying pattern. People feel less bad. They make fewer changes to the structural conditions producing the depression. The protocol becomes a maintenance frame for a problem that wanted a more disruptive intervention.
This is the founder population blind spot. Microdosing-as-self-treatment is comfortable. The dose is low, the ritual is contained, and the felt benefit is real. But the comfort is exactly what makes it a poor fit for the kind of depression that needs structural change, whether that is sleep, work intensity, relationships, or the deeper patterns that show up in integration work. The molecule can become the thing that lets you not look at the pattern.
What Are the Real Risks of Microdosing for Depression?
Three risk categories deserve more attention than productivity-oriented coverage typically gives them, and the depression context makes each of them sharper because depressed users are more likely to sustain protocols longer and attribute changes to the substance more strongly. The long-term picture is poorly characterized. Acute risk is low. The misattribution problem is the largest concern.
Tolerance and the Six-Week Drop-Off
Tolerance to psilocybin develops within days of consecutive dosing and re-accumulates over months of consistent protocol use. Most users on Fadiman-style protocols report diminishing felt effects between weeks four and six. For someone microdosing for depression, this drop-off often coincides with mood recurrence, which is interpreted as needing a dose increase rather than as evidence that the substance-specific contribution was smaller than the protocol-level contribution all along. The dose creeps up. The risk profile creeps up with it.
Cardiac Valvulopathy Risk in Long-Term Use
Chronic activation of 5-HT2B serotonin receptors has been linked to cardiac valvulopathy in the fenfluramine and pergolide literature. Nichols and colleagues have raised the concern that sustained microdosing, by chronically engaging 5-HT2B, could carry analogous long-term cardiac risks. The evidence is theoretical rather than demonstrated. The precedent is not. Multi-year microdosers for depression, particularly those who scale up doses as tolerance develops, are running an experiment that no one is monitoring with echocardiographic follow-up.
Misattribution and Delayed Treatment
The largest risk for depressed users is not pharmacological. It is the slow displacement of evidence-based treatment by an under-evidenced protocol. Someone who feels meaningfully better on a microdose protocol may not seek psychotherapy, may not consult a clinician about an SSRI, may not pursue a high-dose psilocybin session even where available. If the felt benefit is mostly expectation and behavior change, the underlying depression remains untreated. When the protocol stops working, often around month six, the user is no closer to clinical care than they were at the start, and they have lost the months in between.
The Szigeti 2021 self-blinding RCT in eLife found near-zero objective microdosing effect over placebo across mood and wellbeing outcomes. The Rootman 2022 longitudinal study in Scientific Reports, tracking 8,703 participants, reported real depression reductions in microdosers versus non-microdosing comparators, but without the placebo arm needed to isolate the molecule from the protocol. Goodwin et al. (NEJM, 2022) showed full-dose COMP360 psilocybin produced 29% sustained remission in treatment-resistant depression at week three, a class of effect microdosing has not demonstrated in any controlled trial. Together, the three studies suggest microdosing for depression is best understood as a structured behavioral intervention with a felt placebo response, not as an antidepressant pharmacotherapy in the sense full-dose psilocybin or SSRIs are.
How Should Someone Think About Integration After Microdosing for Depression?
Most founders who arrive at integration work after months of microdosing carry two things at once: a real felt shift in mood and motivation, and unclear attribution about what produced it. The integration question for microdose users is not the same as for full-dose retreat users, because the experience itself is sub-perceptual. What needs integrating is the behavior change, the felt benefit, and the question of what the substance gave the person permission to do.
The integration framework I use with this group has three layers. The first is straightforward inventory: what changed during the protocol period in sleep, exercise, work hours, alcohol, relationships, and daily structure. Most users discover that several of these changed substantially and that they had attributed the cumulative effect to the substance. Naming the actual behavioral changes makes them portable beyond the protocol.
The second layer is the felt-benefit-versus-underlying-pattern question. If depression softened during microdosing, what was the depression doing before, and is the softening structural or affective? Many users report what they describe as a real internal shift, which holds even after the protocol ends. Others find the benefit fades within weeks of stopping. The difference tells you what the protocol was actually addressing. For deeper detail, see the psilocybin therapy preparation guide.
The third layer is whether higher-dose work or other evidence-based treatment is now indicated. For users whose felt benefit fades and whose underlying depression remains, microdosing was a useful starting point that has reached its ceiling. The honest next step is often clinical care, ranging from psychotherapy and SSRIs through to full-dose psilocybin therapy in regulated jurisdictions. Microdosing has done its work if it has moved the user closer to the conversation about real treatment, not further from it.